Skip to search formSkip to main contentSkip to account menu

SDZ HTF 919

Known as: HTF 919, SDZ HTF-919 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
REASONS FOR PERFORMING STUDY It has been shown that the selective 5-HT4 receptor agonist tegaserod induces an increase in… 
2001
2001
Tegaserod (HTF 919) is a selective 5‐HT4 receptor partial agonist in development for the treatment of irritable bowel syndrome. 
2001
2001
Tegaserod (HTF 919) is a highly specific 5‐HT4 receptor partial agonist that exhibits promotile activity throughout the… 
Highly Cited
2000
Highly Cited
2000
Tegaserod (HTF 919), a 5‐HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in… 
Highly Cited
1999
Highly Cited
1999
Previous studies have shown that the intestinal peristaltic reflex initiated by mucosal stimulation is mediated by release of 5… 
Highly Cited
1999
Highly Cited
1999
Tegaserod (HTF 919) is a new drug being developed for gastrointestinal motility disorders. Because other gastrointestinal… 
1999
1999
This study assessed the pharmacokinetic profiles of administering tegaserod (HTF 919) at different time intervals with respect to… 
Highly Cited
1997
Highly Cited
1997
Effects of the nonbenzamide 5-hydroxytryptamine4 agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to…